Skip to main content
. 2022 Dec 14;23(24):15924. doi: 10.3390/ijms232415924

Figure 1.

Figure 1

Course of LDL cholesterol under bulevirtide treatment in individual participants. Primary endpoint was change in LDL cholesterol after 12 weeks of treatment (Visit W13D1, highlighted): Participants with decrease of LDL cholesterol > 19.6 mg/dL in blue (“responder”); participants with no decrease and decrease < 19.6 mg/dL of LDL cholesterol in red (“non-responder”). Green: Hodges–Lehmann estimator with 95% confidence interval.